Get the Stockscreener App
1.64
1.20%
-0.02
Immunoprecise Antibodies Ltd stock is traded at $1.64, with a volume of 991.09K.
It is down -1.20% in the last 24 hours and up +50.46% over the past month.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
See More
Previous Close:
$1.66
Open:
$1.6
24h Volume:
991.09K
Relative Volume:
0.43
Market Cap:
$71.48M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-3.4585
EPS:
-0.4742
Net Cash Flow:
$-5.90M
1W Performance:
-24.07%
1M Performance:
+50.46%
6M Performance:
+252.54%
1Y Performance:
+90.03%
1-Day Range:
$1.52
$1.64
1-Week Range:
$1.52
$2.29
52-Week Range:
$0.30
$2.41
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Compare IPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
1.64 | 75.97M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
Why is ImmunoPrecise Antibodies Ltd. stock attracting strong analyst attentionWealth Building Planner With Proven Results - jammulinksnews.com
ImmunoPrecise Antibodies Announces Details for October 2025 Annual Meeting - TipRanks
Does ImmunoPrecise Antibodies Ltd. stock perform well during market downturnsFinancial News Updates For Consistent Profits - jammulinksnews.com
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q4 2025 Earnings Call Transcript - MSN
What does recent volatility data suggest for ImmunoPrecise Antibodies Ltd.Technical Entry Plan with Risk Minimization - Newser
Is ImmunoPrecise Antibodies Ltd. stock bottoming outFree Accurate Buy Point for Momentum Stocks - Newser
Is ImmunoPrecise Antibodies Ltd. stock ready for a breakoutWeekly Chart-Based Forecast for Traders - Newser
ImmunoPrecise Antibodies Full Year 2025 Earnings: Misses Expectations - Yahoo.co
How Efficient Is ImmunoPrecise Antibodies Ltd. at Controlling Operating CostsTechnical Trade Plan with Entry Checklist - Newser
Is ImmunoPrecise Antibodies Ltd. forming a reversal patternFree Swing Setup With Technical Confirmation - Newser
ImmunoPrecise Antibodies Ltd (IPA) Q4 2025 Earnings Call Highlights: Record Revenue and ... - Yahoo Finance
Detecting support and resistance levels for ImmunoPrecise Antibodies Ltd.Short Term Opportunity Finder with Tools - Newser
ImmunoPrecise Antibodies Ltd. Reports Strategic Focus Amid Financial Challenges - TipRanks
ImmunoPrecise Antibodies Reports Record Revenue and Growth - TipRanks
ImmunoPrecise Antibodies Q4 2025 Earnings Call Transcript - MarketBeat
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates - MSN
What technical models suggest about ImmunoPrecise Antibodies Ltd.’s comebackFree Fundamental Winners With Safe Entry Plan - Newser
Investors ignore increasing losses at ImmunoPrecise Antibodies (NASDAQ:IPA) as stock jumps 15% this past week - simplywall.st
Earnings call transcript: ImmunoPrecise sees record revenue in Q4 2025 - Investing.com
ImmunoPrecise Bets Big On BioStrand Growth And AI Focus - Finimize
Why ImmunoPrecise Antibodies Ltd. stock attracts strong analyst attentionMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Immunoprecise Antibodies Ltd reports results for the quarter ended April 30Earnings Summary - TradingView
ImmunoPrecise Antibodies Reports Record Fiscal Year 2025 Results - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA - Yahoo Finance
ImmunoPrecise Antibodies' Impressive One-Year Returns Amid Underlying Losses and Revenue Growth Concerns. - AInvest
Is ImmunoPrecise Antibodies Ltd. stock a good hedge against inflationLong-Term Investment Strategy Summary Guide - Newser
ImmunoPrecise Antibodies Ltd. Stock Support and Resistance Levels You Should KnowReal Stock Picks With Setup Verification - Newser
Published on: 2025-07-29 02:55:04 - Newser
What makes ImmunoPrecise Antibodies Ltd. stock price move sharplyTop Growth Ideas For 2025 - jammulinksnews.com
What are the technical indicators suggesting about ImmunoPrecise Antibodies Ltd.Smart Portfolio Watchlist To Watch Now - jammulinksnews.com
What are analysts’ price targets for ImmunoPrecise Antibodies Ltd. in the next 12 monthsTrack high-yield stocks before they peak - jammulinksnews.com
What are the latest earnings results for ImmunoPrecise Antibodies Ltd.Breakthrough capital growth - jammulinksnews.com
Is ImmunoPrecise Antibodies Ltd. a growth stock or a value stockMaximize returns with expert trading insights - jammulinksnews.com
Is it the right time to buy ImmunoPrecise Antibodies Ltd. stockInvest smarter with actionable trading signals - jammulinksnews.com
What is ImmunoPrecise Antibodies Ltd. company’s growth strategyInvest confidently with professional market insights - jammulinksnews.com
How ImmunoPrecise Antibodies Ltd. stock performs during market volatilitySmart Money Signals - Newser
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):